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Huntington’s Disease (HD) is a fatal, autosomal dominant, neurodegenerative disorder caused by 
a CAG repeat expansion in the huntingtin gene.  The disease is characterized by chorea, as well as 
psychiatric and cognitive symptoms.  At present, no treatment able to modify the disease 
progression is available.  HD is characterized by the death of medium striatal spiny neurons within 
the brain.  Melatonin is a hormone which acts as a neuroprotectant in a variety of 
neurodegenerative diseases.  While most endogenous melatonin is produced by the pineal gland 
and circulated in the bloodstream, melatonin is also present in neurons.  Here I use a novel method 
of detecting site specific melatonin synthesis to show melatonin is synthesized in neuronal 
mitochondria, where melatonin receptors are also localized.  Previous research shows the 
melatonin receptor MT1 to be the mechanism of melatonin’s neuroprotection in cell and mouse 
models of HD.  Here I measure the expression of MT1 in the R6/2 mouse model of HD to compare 
with literature reported decrease in expression, and test the effects of the R6/2 phenotype on 
overexpression of MT1 in a transgenic MT1 mouse model (NSE-MT1).  Further, I use the cross 
of the NSE-MT1 mouse model and R6/2 to assess the effects of overexpression of MT1 in 
increasing melatonin’s neuroprotective properties to ameliorate disease phenotypes including 
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caspase activation, neuronal density, rotarod behavioral testing, and survival.  Together, these data 
show overexpression of MT1 produces small increases in melatonin’s neuroprotective properties 
with regard to caspase activation, but this protective effect does not cause corresponding increases 
in behavioral deficits or survival.  Neuroprotection by melatonin is partially mediated by the MT1-
receptor in an HD mouse model, but may additionally function by alternate pathways or be 
modulated by regulatory mechanisms.  Understanding melatonin’s role as a neuroprotectant can 
help with the development of melatonergic therapeutics to treat HD and other neurodegenerative 
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1.0    INTRODUCTION 
1.1 HUNTINGTON’S DISEASE 
George Huntington first described a hereditary disease with a defining symptom of chorea in 1872 
when he observed a rare disease that occurred among select families of Long Island1.  Although 
Huntington’s disease (HD) had a distinct genetic signature, it was over a century later that a 
causative gene, originally called IT15 for its interesting transcript, was mapped to 4p16.32.  Shortly 
after, a single gene, huntingtin (HTT), was identified, with the disease causing element found to 
be an expanded trinucleotide repeat of CAG in the first exon of the gene3.  HTT is 180kb, with 67 
exons ranging in size from 48-341 base pairs in length4.  
HD occurs in approximately 5.7 per 100,000 individuals in North America, with an 
estimated 30,000 individuals with manifest HD in the United States.  The disease prevalence varies 
greatly by population, attributed to different haplotypes of average CAG tract size.  HD prevalence 
is 10 times greater in European populations compared to Asian and African populations5.  The 
disease is passed with an autosomal dominant pattern of inheritance. 
The CAG expansion in exon 1 and the correlations between repeat length and HD 
manifestation are extensively studied.  Individuals with fewer than 27 repeats have no disease risk.  
An intermediate range of 27-35 CAG repeats is not disease causing in individuals, but is considered 
a higher risk for transmitting a pathogenic repeat length to offspring6.  Individuals with 36 or more 
repeats are at risk for developing HD within their lifetime.  A very strong negative correlation 
exists between CAG repeat length and age of disease onset7-10.  While a longer repeat length 
correlates with an earlier age of onset, the type of symptoms and order of their manifestation does 
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not seem to be determined by repeat length9.  However, while individuals may appear similar in 
their symptoms and disease onset, those with longer repeats tend to have a faster disease 
progression8. 
While the correlation is strong, repeat length does not account for all variability in age of 
onset.  In an extensive study among Venezuelan HD populations, repeat length was determined to 
account for about 70% of variability in age of onset11, although other work estimates it closer to 
50%9.  Among the Venezuelan population, the remaining variability was estimated to be 40% due 
to other genes and 60% due to environmental factors.  Follow-up linkage analysis mapped specific 
loci for other genes, which may modify HTT, but individual genes have not been identified12. 
HD is subject to a strong anticipation effect.  The CAG repeats in the HTT gene are often 
unstable, and the repeat length can increase from parent to child.  It is via this anticipation that 
intermediate repeat length individuals can pass a pathogenic repeat length to their offspring.  This 
effect is more likely when the disease-causing allele is passed paternally.  One theory for this is 
that the frequent production of sperm allows for a greater chance of mitotic instability13.  Even 
within individuals, there can be instability and variation in CAG repeat length.  Some instability 
occurs within somatic tissues, including different neuronal cell types with a high amount of 
variability in striatal cells14.  However, because the disease causes neurodegeneration, it is not 
clear whether CAG variability in neuronal cells is due to mutant HTT causing selective cell death 
or if the neurodegeneration causes mitotic instability. 
HD symptoms in adults typically present around 35-45 years of age, although about 3-10% 
of cases are juvenile, occurring in individuals under 21 years of age, a subset with very high CAG 
repeat length15,16.  The hallmark symptom of the disease is chorea; brief, non-repetitive, non-
rhythmic jerking movements.  However, in a prodromal stage before chorea and other physical 
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symptoms manifest, individuals show a shift in mood and cognitive difficulties17.  Patients often 
under-notice or are unaware of these early symptoms, a characteristic which may itself be caused 
by the disease18.  Cognitive difficulties include problems with memory, visuospatial cognition, and 
ability to manipulate learned information.  In juvenile HD, cognitive symptoms can be seen via 
academic ability, difficulties reading, and regression of language skills15.  As many as half of all 
HD patients present with psychiatric symptoms prior to motor symptoms, although the type, 
severity, and onset of these psychiatric symptoms are not correlated with CAG repeat length19.  
Depression is common, and the suicide rate among HD patients is up to 10 times higher than that 
of the general population17; an estimated 30% of patients attempt suicide at least once after their 
diagnosis20.  Patients also frequently report problems with sleep patterns, both in adult and juvenile 
variants of the disease.  As the disease progresses, the more distinct physical symptoms manifest.  
Chorea is a common marker of disease onset, although it is not an indicator of disease severity.  
Dystonia, which causes involuntary muscle movements, is associated with earlier onset21.  Another 
symptom, motor impersistence, is characterized by an inability to sustain voluntary muscle 
movements; because its presence is not correlated with presence of chorea, motor impersistence 
may be a particularly consistent marker of disease progression.  HD patients show a clear decrease 
in body mass index (BMI), which is progressive over the course of the disease, and the severity of 
weight loss is correlated with CAG repeat length22-24.  Patients exhibit no endocrine or 
gastrointestinal abnormalities, and the change in BMI appears to be due to a hypermetabolic state, 
although the exact mechanism is unclear25.  In juvenile HD, seizures occur in 30-50% of cases15.  
While many symptoms are common within the disease, they do not establish a clear cause of death 
in HD patients.  Leading causes of death for HD are pneumonia, cardiovascular disease, wasting, 
and suicide26. 
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HD has clear neuropathology.  Patients have a dramatic decrease in brain weight, which 
can be as much as 30% smaller than a non-HD brain at autopsy.  This is due to atrophy and neuronal 
death, beginning in the caudate nucleus and putamen.  By late stage disease, up to 95% of neurons 
may be lost in the caudate nucleus27.  As the disease progresses, whole brain atrophy occurs, and 
this combination of neuronal death and atrophy can occur before clinical symptoms begin to 
manifest28.  Neuronal death begins selectively, primarily affecting medium spiny neurons in the 
caudate, with the earliest loss seen specifically in GABA/enkephalin neurons.  As the disease 
progresses, loss of cortical neurons is likely the cause of cognitive and behavioral symptoms, as 
well as affecting motor pathways resulting in chorea29. 
Recent research in HD shows the strong role apoptosis plays in neurodegeneration, and 
indicates this may be a mechanism for the cellular damage seen in the disease.  Programmed cell 
death is seen throughout neurodegenerative diseases including Alzheimer’s and ALS, as well as 
in stroke. 
In programmed cell death, a biochemical cascade is set off which includes the activation 
of caspases and results in fragmentation of the nucleus.  The cascade is a complex interplay of 
molecular components, and while the process is a natural function, a change in any one step can 
result in undesired cell death. 
Caspases, short for cysteine-dependent aspartate specific proteases, are primary factors in 
apoptosis.  Since the discovery of caspase 1 (or interleukin-1β-converting enzyme), a total of 11 
caspases are identified in humans.  These small molecules begin as procaspases, molecules with a 
recruitment domain on the N-terminal.  Variety in the recruitment domains inform where along 
the cell death cascade each caspase functions: upstream or downstream, initiating or executing.  
The N-terminal domain of most upstream molecules (procaspases 1, 2, 4, 5, 9, 11, 12, 13) is a 
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caspase-recruiting domain (CARD).  There are also two caspases (8 and 10) which have a death-
effector domain (DED) at the N-terminus.  These upstream caspases function to initiate the process 
of apoptosis. The other caspases (3, 6, 7, 14) have a short prodomain30.  These caspases function 
in actual executing of the cell by both destroying cellular structures and degrading DNA16. 
Apoptosis can occur through intrinsic mitochondrial mediated pathways or extrinsic death 
receptor pathways. While apoptosis has traditionally been described more broadly, more recent 
understanding has noted that this type of cell death is defined by the activation and involvement 
of caspases31.  Initial signaling to induce this caspase-mediated cell death pathway can come from 
increased levels of free radicals or intracellular calcium, or from pro-apoptotic signals from 
proteins of the BCL2 family.  Proteins within the BCL2 family can act as inhibitors or promoters 
of apoptosis32,33.  For example, upstream of the mitochondria, caspase 1 cleaves Bid, a protein of 
the Bcl-2 family 34.  After this cleavage, the truncated Bid protein (tBid) translocates to the 
mitochondrial membrane.  There, it interacts with BCL2 family proteins Bcl-XL and Bax, resulting 
in a release of cytochrome c from the mitochondria35. 
These signals lead to the release of apoptotic factors from the mitochondria, following both 
caspase dependent and caspase independent pathways.  Critically to the caspase mediated cell 
death, cytochrome c is released from the mitochondria.  Cytochrome c then binds Apaf-1 and pro-
caspase 9 to form the apoptosome and activate caspase 936.  Activated caspase 9 then cleaves and 
activates caspase 3, which proceeds to effect cell death. 
Cell death is an important regulatory element in biological systems. Disrupting the caspase 
mediated cell death pathway can have significant negative effects in a healthy organism.  For 
example, caspase 9 knockout mice show overgrowth and malformation of brain tissue, due to a 
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lack of apoptosis during development37.  Conversely, in many neurodegenerative diseases, caspase 
activity is increased and apoptosis function is altered38. 
Notably, in HD, several caspases are activated. In both mice and humans, caspase 1 showed 
increased activity beginning early in the disease progression, while inhibition of caspase 1 slows 
the disease progression in the R6/2 mouse39.  Similarly, caspase 3 activation is increased in both 
mouse models and human patients, and inhibition results in extended survival of the R6/2 model40.  
Additionally, caspase 9 activation and cytochrome c release are also increased in HD human and 
HD mouse model brains41.  The increased activity of caspase 3 and 9 occurs later in the disease 
progression, whereas increased caspase 1 activity is seen earlier39,41.  While the changes in caspase 
activity illustrate a key mechanism of HD pathology, they also provide an important mechanism 
for treatment as the restoration of their appropriate activity results in clear improvement to the 
disease phenotype. 
1.1.1 HD Mouse Models 
Due to its clear genetic cause, HD is particularly well suited for animal modeling.  There are 
several methods by which mouse models of HD are generated.  Models use either an insertion of 
human HTT or alter the mouse homolog, the Hdh gene42.  Knock-in of CAG repeats into the mouse 
Hdh gene include models such as HdhQ111, which uses the endogenous Hdh promoter.  These 
knock-in models are created by either expanded repeats in the mouse gene or, as is the case in the 
zQ175 model, with a chimeric exon 1 combining both human and mouse regions43.  Insertion of 
the human HTT is done with either a fragment or full length model44.  Full length models have the 
entirety of the human HTT gene inserted into the mouse genome using yeast or bacterial artificial 
chromosomes.  Common full length models include YAC128 and BacHD44.    Because the 
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pathogenic polygluatmine repeat in humans is in the first exon of the HTT gene, some models 
insert only the first exon of human HTT.  Common fragment models include R6/2 and N171-82Q.  
Promoters vary among models42.  While full length models are genetically more similar to human 
HD, the fragment models tend to produce a more robust observable phenotype45. 
Because of the variation in the gene, polyglutamine tract size, and promoter variations, it 
is difficult to compare studies between mouse models46.  Additionally, characterizing the modeled 
aspects of motor, cognitive, and psychiatric symptoms can be difficult in mice due to the way these 
overlap in their manifestation44.  Dysfunction in one aspect may be traced to several possible 
affected neuronal pathways.  However, despite these difficulties, HD model mice provide critical 
insight into the disease pathology, particularly useful for measuring therapeutic outcomes. 
One of the most common and best characterized of the HD mouse models is the R6/2 
mouse.  This first mouse model of HD was developed by Mangiarini, et al., in 1996 as one of 
several R6 mice, each with a different number of CAG repeats in the exon 1 insert.  All R6 mice 
use the human HTT promoter.  The R6 mice were developed on a hybrid background of F1 
offspring of CBA and C57/BL6 mice (B6CBAF1).  While attempts were made to maintain the line 
only mating with C57/BL6, poor litter sizes required that the R6 lines be bred on a background 
with more robust breeding, the B6CBA line.   Of the original lines, R6/1 and R6/2 continued to be 
used for follow-up experimentation, with R6/2 being the most common. 
R6/2 mice average around 144 CAG repeats47.  This polyglutamine track is considerable 
larger than even most juvenile HD patients and results in a very severe and rapid phenotype.  R6/2 
mice present with a progressive phenotype with onset around 7-8 weeks of age, which rapidly 
becomes more severe and ends in death around 13-14 weeks of age47. 
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Similar to patterns of symptoms in human disease, the mice exhibit motor symptoms 
including chorea-like movements, mild ataxia, resting tremor, and involuntary stereotypic 
movements such as stroking of the face and kicking of hindlimbs.  In tests of motor performance 
and grip strength, the R6/2 mice show progressive decline with age45.  The mice exhibit normal 
weight gain from weaning until disease onset when they plateau and then begin to lose weight.  
This weight loss is consistent in both male and female R6/2, although males exhibit more severe 
loss45.  Despite continuing to eat normally, R6/2 mice lose both body weight and muscle mass, 
similar to what is seen in human HD patients47.   While approximately 25% of R6/2 mice develop 
diabetes mellitus, this does not appear to affect survival, weight loss, or motor test performance48.   
As in juvenile HD, R6/2 mice occasionally have seizures, although these are not well 
characterized and the cause is unknown.  Rarely, mice die as a result of seizure (less than 2% of 
deaths)45.  No comprehensive work currently exists documenting cause of death in R6/2 mice46.  
The second most common cause of death in HD patients is cardiovascular defects26,49, and R6/2 
mice show cardiac dysfunction as well.  Reduced cardiac output seen at 8 weeks and by 12 weeks, 
heart weight is decreased49.  This may be a significant contributing factor to R6/2 death, and is 
currently the only potential cause that has been investigated.  While cause of death is not well 
understood, survival is consistently used as a reliable indicator of neuroprotection in therapeutic 
studies45. 
R6/2 mice model several key pathological features which are believed to individually or 
collectively influence HD in humans, including protein aggregates, mitochondrial dysfunction, 
synaptic dysfunction, and cell death and autophagy46.  The brains of R6/2 mice are significantly 
smaller than those of wild type littermates, with approximately 19% reduction seen by late stage 
disease.  At both 60 and 90 days of age, significant loss is seen specifically in striatal neurons; this 
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loss is believed to account for a large portion of overall reduction in brain mass45.  R6/2 mice also 
are one of the few HD models which have intranuclear inclusions; these protein aggregates are 
most prominent in striatal neurons with 98% of these cells affected by 12 weeks46. 
1.2 MELATONIN & SIGNALING 
1.2.1 Melatonin 
N-acetyl-5-methoxytryptamine, better known as melatonin, is a hormone found in mammals 
synthesized from the amino acid tryptophan.  Melatonin was first discovered and isolated in 
196050, and later found to play roles in circadian rhythm and antixodiation51,52.  Melatonin has 
multiple functions, acting both as an antioxidant and through receptor-mediated signaling. 
Melatonin is primarily known for being synthesized in the pineal gland, which cyclically 
regulates serum melatonin levels according to a light/dark pattern 53.  However, intracellular levels 
of melatonin do not follow this same circadian pattern 54.  The highest concentration of extrapineal 
melatonin in the body is found in the brain, and within the cell it is highest in the mitochondria 
54,55.  While the majority of melatonin is synthesized in the pineal gland, early research estimated 
about 20% of melatonin is synthesized extrapineally 56.  Recent work in the Friedlander laboratory 
found that this extrapineal melatonin is synthesized in the mitochondria [manuscript in 
preparation].  Cultured neural stem cells have melatonin present, and the amount of melatonin 
increases with differentiation, supporting the hypothesis that neuronal cells may produce 
melatonin 57. 
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In rats and humans, levels of melatonin decrease with age.  In humans, the serum melatonin 
levels peak during childhood, and a 3.5 fold reduction was seen between age groups 35-50 years 
and 70-90 years of age 58.  Beyond this normal physiologic reduction with age, plasma melatonin 
levels in HD patients are sharply reduced and progressively decreases with disease 59,60.  This 
corresponds with sleep disturbances noted in 60-80% of HD patients 61. 
In mouse models, melatonin production can vary.  Pineal melatonin production follows 
circadian cycling in CBA and C3H mouse strains 62.  C57Bl/6 mice are enzymatically 
compromised in their ability to synthesize melatonin 63, but still express low levels of serum 
melatonin 62.  The mechanism for this contradiction remains unclear. 
The HD model R6/2 mice, which are bred on the B6CBA background, an F1 hybrid of 
CBA and C57Bl/6, have progressive disturbed circadian patterns, sometimes showing complete 
sleep-wake cycle reversal at late stages of disease 64.  While plasma melatonin has been shown to 
be altered in these mouse strains, intraneuronal melatonin has never been measured. 
1.2.2 MT1 receptors 
Melatonin signaling in mammals is mediated by two melatonin receptors, MT1 (officially 
MTNR1A, previously Mel1A) and MT2 (officially MTNR1B, previously Mel1B).  The melatonin 
receptors are their own subgroup of G-protein coupled receptors.  They consist of 7 transmembrane 
alpha helical segments transversing the membrane.  Both receptors are found on the cell membrane 
65 , and recent work shows they are also localized to mitochondrial membrane65.  The human MT1 
gene is mapped to 4q35.1 66 and the mouse Mt1 is located on chromosome 8 67. 
MT1 and MT2 are high affinity binding receptors, with MT1 showing a stronger affinity 
to 125I-melatonin than MT268.  Melatonin binds the receptor, resulting in a conformational change 
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in G-alpha-I.  This change results in inhibition of cAMP formation and PKA activity, as well as a 
decrease in CREB phosphorylation69-71.  Additionally, through coupling with other G proteins, 
activation of MT1 results in activations of many other G proteins. 
G protein coupled receptors were previously believed to function as monomers, but more 
recent work shows not only do they form dimers, but this may be the primary or only form of 
functioning72.  However, the biological significance of these dimers is unclear.  MT1 and MT2 
form both hetero- and homodimers.  Significantly, GPR50 also interacts with these proteins.  
GPR50 is a G protein of unknown function which is considered a “melatonin-related receptor”73.  
GPR50 is mapped to the X chromosome, and shares 45% amino acid homology with MTNR1A 
and MTNR1B74,75.  Notably, GPR50 forms heterodimers with both MT1 and MT2.  This 
dimerization significantly decreases the ability of MT1 to bind melatonin76.  The exact mechanism 
of this inhibition is unknown, but may be due to GPR50 preventing critical interactions of MT1 
and other proteins, including recruitment proteins. 
Expression of pineal melatonin receptors reduces 1.75 fold with human aging; a fold 
change is seen in early stage Alzheimer’s disease, with a progressive decrease through late stage 
of the disease77.  Similarly, a 50% reduction in pineal melatonin receptors is seen in Parkinson’s 
disease78.  Extrapineal melatonin receptor expression also shows a decrease with aging in rats 79.  
In R6/2 mice, expression of MT1 but not MT2 is reduced with disease progression; this same 
pattern is also seen in post-mortem human HD brains65. 
In C3H mice, Mt1 mRNA and protein levels show daily fluctuations, high during the day 
and low at night, opposite the pattern of melatonin.  Mt1 mRNA in these mice is expressed in the 
brain in striatum, substantia nigra, and ventral tegmentum 80. 
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Therapeutic use of melatonin is considered very safe, including for long term use and 
during pregnancy 57.  Both melatonin and melatonin receptor agonists are available currently, with 
few known side effects.  Agomelatine, a receptor agonist, is approved for treatment of depression 
in Europe; ramelteon, another receptor agonist, is approved in the U.S. for treatment of insomnia.  
Over-the-counter melatonin is available as a supplement in the U.S., and an extended release 
melatonin formulation, Circadin, is available in Europe 81.  Exogenously administered melatonin 
has a half-life of about 30 minutes 54.  
1.2.3 Melatonin receptor mice 
Mouse models are used extensively to study various roles of the melatonin receptors.  MT1 
knockout mice have decreased REM sleep time, with MT1 and MT2 playing complementary but 
distinct functions in sleep cycles82.  Another knockout model showed a loss of blood glucose 
cycling rhythm, indicating the time dependent regulatory functions of MT1 extend beyond sleep83.  
Knockout of MT1 also results in an increase in intraocular pressure, death of retinal ganglion cells 
and increased reduction of photoreceptors with age84,85.  Additionally, a knockout MT1 mouse 
model showed sensorimotor defects and an increase in depression, indicating MT1 plays a 
significant role in behavioral outcomes86.  While studies with knockout MT1 mice have been 
performed in a variety of contexts, no previous studies have been done overexpressing the MT1 
gene. 
The role of MT1 in neuroprotection is subject to contradictory evidence.  A study using 
MT1/MT2 double knockout mice treated with melatonin showed no protective effect on ischemic 
brain injury, suggesting the receptors were not the mechanism for melatonin’s neuroprotection87.  
However, work in the Friedlander laboratory found melatonin’s mechanism to specifically be 
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through MT1 in vitro65.  To address these contradictions and clarify MT1’s role in neuroprotection, 
more data is needed. 
Therefore, in order to better understand the role of MT1 in neuroprotection, the Friedlander 
laboratory developed a transgenic mouse to overexpress MT1.  The transgene consists of a human 
MT1 receptor gene, which is attached to a FLAG tag and EGFP sequence at the 3’ end and 
controlled by a neuron-specific enolase promoter (NSE) (see figure 1).  The NSE promoter 
expresses the transgene in primarily neurons; the promoter can also express sporadically in testes 
and kidneys88,89. 
Two founder mice were created for this transgenic model, labeled 2604 and 2606, on a 
B6CBA background. Both lines express the transgenic NSE-MT1 mRNA [personal 
communication, Yalikun Suofu, University of Pittsburgh].  My work uses the 2604 line, which is 
a more prolific breeder. 
Characterization of the MT1 transgenic mouse is ongoing.  Both body weight and brain 
weight are comparable to wild type B6CBA mice.  Their brain volume is the same as that of wild 
type mice and they show no changes in number of cortical or motor neurons [personal 
communication, Amanda Mihalik, University of Pittsburgh].  NSE-MT1 mice kept for breeding 
had a lifespan of 18-24 months, similar to that expected of wild type B6CBA.  
NSE Human Flag GFP 
MT1 
Figure 1. Transgenic NSE-MT1 mouse construct 
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The NSE-MT1 mouse was developed on the B6CBA background specifically so that it 
could be crossed with the R6/2 mouse for HD research.  The use of both the R6/2 and NSE-MT1 
mouse models allows for an excellent method to study the role melatonin and melatonin receptors 
play in ameliorating the pathology of HD. 
1.3 PREVIOUS STUDIES 
Apoptosis and mitochondrial dysfunction are important components of neuronal death in 
neurodegenerative diseases.  As a result, they provide a promising target for therapeutic drugs.  In 
order to screen for possible therapeutic drugs, the Friedlander laboratory used the 
Neurodegeneration Drug Screening Consortium of 1040 compounds, a library of drugs put 
together by NINDS90.  All of the compounds within the library are already FDA approved, making 
them ideal for therapeutic repurposing.  These drugs were initially screened using isolated 
mitochondria, creating a cell-free method of screening.  Follow-up screening was conducted in 
whole cell models. 
The screened compounds were narrowed down by several criteria: ability to inhibit 
cytochrome c release, ability to inhibit cell death, and limited cell toxicity90.  They were compared 
against the antibiotic minocycline.  Minocycline inhibits the release of cytochrome c and has a 
neuroprotective effect in models of Huntington’s, Parkinson’s, ALS, and stroke91.  From this 
screening, sixteen compounds, including melatonin, were selected for further testing92. 
Using primary cortical neurons (PCNs) exposed to oxygen glucose deprivation (OGD), 
which induces the release of cytochrome c and the activation of caspase-3, the Friedlander group 
quantified the protective effects of melatonin92.  They then compared the protective effect against 
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H2O2 and NMDA induced cell death.  In all of these cases, melatonin was effective in protecting 
against cell death92.  It reduced overall death, as well as reduced apoptotic specific mechanisms of 
nuclear fragmentation and chromatin condensation. 
To further understand the mechanisms of this protection, the researchers looked 
specifically at the release of cytochrome c and AIF from the mitochondria.  Melatonin was able to 
block the release of these molecules, as well as inhibit the subsequent activation of caspase-392.  
Melatonin was also able to inhibit the release and activation of caspase-192. 
Additionally, melatonin was able to inhibit the loss of mitochondrial membrane potential 
resulting from OGD in PCNs92.  This indicates that the mechanism involved is not just inhibiting 
the release of molecules from the mitochondria, but also functions by maintaining normal cellular 
function. 
However, in studying mitochondrial permeability, it was found that melatonin does not 
reduce or inhibit this.  It also did not have an effect on mitochondrial membrane potential in 
isolated mitochondria. 
The Friedlander laboratory previously investigated the role melatonin receptors play in HD 
models of neurodegeneration.  Cytochrome c colocalization was looked at in cell cultures of striatal 
cells ST14A with mutant HTT.  When the cells were put into nonpermissive conditions (a shift 
from 33°C to 37°C), they released cytochrome c from the mitochondria.  When these cells were 
treated with melatonin, the release of cytochrome c was inhibited.  Melatonin also was able to 
partly inhibit the release of SMAC and AIF65. 
The Friedlander researchers further investigated the role melatonin receptors play in 
neuroapoptosis.  Luzindole is a melatonin receptor antagonist and 2-iodomelatonin is an agonist.  
Using these molecules, they were able to determine that the neuroprotective effect of melatonin 
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requires binding to the melatonin receptor65.  Additionally, knockdown of MT1 resulted in 
increased cell death; conversely, an increase in MT1 in cell models resulted in neuroprotection65. 
Progressing to in vivo models of HD, the research group found that administration of 
exogenous melatonin extended survival, delayed disease onset, and slowed disease progression 
within the R6/2 mouse model of HD.  Additionally, it was found that the levels of MT1 are 
decreased in the brains of these mice, although this depletion can be ameliorated with the addition 
of exogenous melatonin65. 
1.4 CURRENT RESEARCH AND EXPERIMENTAL RATIONALE 
Previous research shows a complex interplay between mitochondria, melatonin, and MT1 as they 
contribute to neuroprotection.  My work aims to further understand the interactions of melatonin 
and MT1 and how this can be used to understand neuroprotection in HD. 
Using the Friedlander generated transgenic MT1 overexpressing mouse and the well-
known R6/2 mouse model, I determined whether increasing melatonin signaling via the MT1 
receptor would further ameliorate symptoms and pathology of the HD model. 
The R6/2 mouse’s modeling of HD is characterized in several ways and my work utilizes 
each of these methods in order to determine the manner and extent of MT1 overexpression effects.  
To test the hypothesis, my work follows these aims: 
1. To determine whether melatonin is synthesized in neuronal mitochondria 
Previous research shows MT1 to be localized to the mitochondria65 and recent data 
demonstrate the neuronal mitochondria contain the terminal two enzymes of the 
melatonin synthesis pathway [manuscript in preparation].  While most plasma melatonin 
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is known to be synthesized in the pineal gland, the putative synthesis of neuronal 
melatonin in mitochondria has not been demonstrated. 
2. To determine the effects of mutant huntingtin on endogenous and transgenic MT1 
MT1 is localized to the mitochondria and previous work by the Friedlander group shows 
that mutant HTT negatively impacts mitochondrial function93.  Expression of MT1 is 
decreased in mutant-HTT cell models; treatment with melatonin significantly ameliorates 
the loss of MT1 protein92.  Increased MT1 has a neuroprotective effect in cell models65.  
Adequate presence of MT1 is necessary for the protective effect of melatonin on the HD 
mouse65.  Here I aim to test whether the HD phenotype specifically affects the expression 
of MT1, both endogenous and transgenic. 
3. To determine the neuroprotective effects of melatonin via the MT1 receptor in an HD 
mouse model 
The previous studies done by the Friedlander group demonstrated a neuroprotective 
effect of melatonin both in vitro and in vivo.  Further, they illustrated that this effect was 
mediated in vitro by MT1.  This study aims to further understand how increasing 
melatonin signaling via MT1 may further ameliorate symptoms and pathology of the HD 
model. 
1.5 PUBLIC HEALTH SIGNIFICANCE 
Huntington’s disease is a devastating and fatal neurodegenerative disease for which there are 
currently no available treatments.  HD patients have a variety of options to treat individual 
symptoms, but no drug is currently available to treat the disease itself 94,95.  An estimated 30,000 
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individuals in the U.S. are living with HD5.  Clinical genetic testing is available which allows an 
individual to know their genetic status, but only about 10-20% of those at risk get the testing 
done96.  Those who test positive have no options for treating the disease they learn is inevitable for 
them. 
While the cause of the disease, a CAG expansion in the HTT gene, has been known for 
over 20 years, many of the mechanisms of the disease itself remain unclear3.  It is important to 
investigate both potential treatments for the disease as well as understand the ways in which these 
may modify the disease. 
Melatonin has been shown to improve outcomes in neurodegenerative diseases such as 
stroke and ALS.  In an HD mouse model, melatonin has been shown to delay disease onset, slow 
progression, and extend survival65.  Melatonin as a therapeutic agent is safe for long term use and 
shows very few side effects 57,81.  Melatonin and melatonin agonists have been approved in both 
U.S. and European markets for treatment of sleep disorders and depression81. 
While the therapeutic use of melatonin has been studied across major neurodegenerative 
disorders, the mechanism of its neuroprotection remains unknown.  Understanding mechanism of 
melatonin can help development of melatonergic drugs in treatment of Huntington’s disease and 







2.0    MELATONIN SYNTHESIS 
2.1 INTRODUCTION 
While most mitochondria is produced in the pineal gland, about 20% is produced extrapineally56.  
The synthesis and location of this extrapineal melatonin has not been extensively studied.  
However, recent research shows that in brain lysates, there is a particularly high concentration of 
melatonin compared to other tissues65.  Additionally, at a cellular level, there is a high 
concentration of melatonin the mitochondria97.  Melatonin has been shown to protect neurons from 
cell death in vitro; additionally, exogenous melatonin is neuroprotective in several in vivo models 
of neurodegeration including ischemic stroke, Parkinson’s disease, ALS, and HD90,92,98-100.  
Neuronal death in HD is believed to be mitochondrially mediated90.  Before further investigating 
the role of mitochondria in the neuroprotective effects of melatonin, it was therefore important to 
understand how melatonin and mitochondria relate. 
Melatonin is synthesized from serotonin, via a multi-step enzymatic process.  Serotonin is 
first converted to N-acetyl serotonin by the enzyme aralkylamine N-acetyltransferase (AANAT).  
Next, N-acetyl serotonin is synthesized into melatonin via the enzyme acetylserotonin O-
methyltransferase (ASMT, also known as HIOMT, hydroxyindole O-methyltranferase)101.  In 
rodents, non-human primates, and humans, these melatonin synthesis enzymes follow a cyclical 
pattern of expression in the pineal gland, with AANAT being the rate-limiting enzyme which 
controls this timed cycle102.  Research in the Friedlander laboratory identified these two enzymes 
are localized to neuronal mitochondria [manuscript in preparation].  This mitochondrial 
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localization was seen across mouse, primate, and human brain samples.  Notably, these enzymes 
do not appear to be light sensitive or cyclical in their expression.   
With melatonin and its synthesizing enzymes localized to the mitochondria along with 
MT1, it was important to test whether these enzymes functionally produced melatonin within the 
mitochondria where it may directly bind the melatonin receptors.  Melatonin was localized to the 
mitochondria via ELISA, but this method could not determine whether the melatonin was 
produced elsewhere and imported or synthesized in the mitochondria itself.  To address this 
question, I collaborated with the University of Pittsburgh Small Molecule Biomarker Core to 
develop a novel method for measuring melatonin synthesis within the mitochondria.  Here I use 
qualitative mass spectrometry to detect the synthesis of intermediate N-acetyl serotonin as well as 
the final melatonin product in isolated mouse brain mitochondria. 
2.2 METHODS 
For each repeat, 5 wild type mouse forebrains were pooled for mitochondrial isolation.  The tissue 
was homogenized with a Teflon homogenizer and spun for 3 minutes at 1300g at 4°C.  The pellet 
was resuspended and spun at the same conditions.  The supernatant of each spin was combined 
and spun for 10 minutes at 21,000g at 4°C and used to isolate synaptosomal and non-synatosomal 
mitochondria according to published methods93,103,104. 
Mitochondria (synaptosomal and non-synaptosomal) (1μg/μL) were incubated in a 
respiration buffer (5 mM HEPES-Tris, 125 mM KCl, 2 mM Pi, 3 μM EDTA, 1 mM MgCl2, 1 mM 
ATP, 5 mM glutamate/malate, 5mM succinate, 10 μM deprenyl) with 50μm d4-serotonin for 30 
minutes at room temperature, then quenched with sodium hydroxide.  For the quantitative 
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experiments, 1ng/ml agomelatine (Sigma A1362), an MT1 agonist with a similar structure to 
melatonin, was added to act as an internal standard.  The solution was extracted into chloroform 
at 5x reaction volume; samples were vortexed to maximize extraction efficiency, centrifuged 
(1000g for 5 minutes), and the resulting non-organic layer discarded. 
Via a collaboration with the laboratory of Samuel Poloyac through the Small Molecule 
Biomarker Core, the samples were analyzed with ultra performance liquid chromatography mass 
spectrometry (Thermo Fisher TSQ Quantum Ultra) for the presence or absence of deuterated 
melatonin.  Transitions used for analysis are 237 → 178 for d4 melatonin and 181 → 164 for d4 
serotonin.  Neat solutions (20 μM) of d4-serotonin, d4-melatonin (66521-38-8, AlsaChim), and n-
acetylserotonin (1210-83-9, Sigma) were run to verify retention times and optimize detection. 
Mitochondrial samples were incubated with either respiration buffer alone or with deuterated 
serotonin.  Respiration buffer with and without deuterated serotonin was also run to verify that 
deuterated serotonin did not spontaneously generate deuterated melatonin in the absence of cellular 
material. 
The mass spectrometry output data were assessed for presence or absence of deuterated N-
acetyl serotonin and deuterated melatonin. 
2.3 RESULTS 
To determine whether melatonin was synthesized in neuronal mitochondria, I incubated 
mitochondria (synaptosomal and non-synaptosomal) with deuterated serotonin.  Because the 
deuterium labeled region of the serotonin molecule is not modified in the process of synthesizing 
melatonin from serotonin, any resulting deuterated melatonin indicated the ability of the isolated
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mitochondria to perform this synthesis.  Indeed, in wild type mouse mitochondrial samples, the 
d4-melatonin metabolite as well as the intermediate molecule, d4-n-acetly-serotonin were detected 
from samples incubated with d4-serotonin (figure 2).  Demonstrating that this outcome is not the 
result of natural degradation of serotonin, samples with d4-serotonin alone, without the presence 
of mitochondria, showed no resulting d4-melatonin. 
The results of the qualitative mass spectrometry provided a solid result indicating that 
melatonin is synthesized in mitochondria.  The enzymes for this synthesis are localized to the 
mitochondria and are functional.   
Figure 2. Melatonin synthesized from serotonin in neuronal mitochondria detected by mass spectrometry. 
Representative chromatograms showing metabolites extracted from mitochondria incubated in control buffer 
(#1,3,5) or with deuterated (d4) serotonin (#2,4,6). Samples incubated with buffer alone show no presence of d4-
labeled metabolites (#1,3,5). Samples incubated with d4-serotonin show detected levels of unprocessed d4-serotonin 
(#2, retention time 1.65 minutes), d4-n-acetyl-serotonin (#4, retention time 2.28 minutes), and d4-melatonin (#6, 
retention time 4.45 minutes). This experiment was repeated three times and this figure is a representative result. For 
1a-d, brain mitochondria were isolated from four mice per experiment, N=3. 
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2.4 DISCUSSION 
Melatonin protects neurons from cell death in HD through a mitochondrially-mediated 
mechanism.  Preliminary data from others in the Friedlander laboratory indicated the enzymes 
needed to synthesize melatonin from serotonin were present in the mitochondria.  With this in 
mind, my work aimed to determine whether neuronal mitochondria synthesized melatonin, where 
it could directly modulate cell death pathways.  Here I utilizes a novel method of detecting 
melatonin synthesis to demonstrate the AANAT and ASMT enzymes localized to the mitochondria 
are functional and melatonin can be fully synthesized from serotonin in mitochondria. The data 
establishes the first known autocrine signaling loop within the mitochondria.  Neuronal melatonin 
is synthesized in the mitochondria, where it can immediately bind to its receptors without transport 
or release from the cell.  These data also illustrate the central role of mitochondria in melatonin 





3.0    MT1 EXPRESSION 
3.1 INTRODUCTION 
Expression of human pineal melatonin receptors has been shown to decline with age, as well as in 
Parkinson’s disease and Alzheimer’s disease 77,78.  Extrapineal melatonin receptor expression has 
also been shown to decrease with aging in rats 79.  In the brains of R6/2 mice, MT1 is decreased 
as compared to wild type, although this depletion can be rescued by treatment with exogenous 
melatonin65.  This rescue capability suggests the presence of a positive feedback mechanism with 
melatonin levels having a positive correlation with MT1 levels.  It is also clear that the HD disease 
phenotype critically interacts with MT1 expression.  My aim here is to characterize how the 
phenotype of standard R6/2 mice affects the expression of both endogenous and transgenic MT1.  
Previous research on MT1 expression in R6/2 mice was done on a unique version of the model 
with a longer CAG repeat length, which lead to atypical disease progression; I sought to replicate 
the reduction of MT1 in the traditional Jax strain of R6/2, with CAG length consistent with the 
original publication of the strain.  Furthermore, I sought to determine whether any reduction in 
endogenous MT1 expression would be mirrored in expression of the transgenic MT1.  To this end, 
I examined the expression of endogenous and transgenic MT1 in wild type, R6/2, and NSE-MT1-





The University of Pittsburgh Institutional Animal Care and Use Committee approved all 
experimental procedures, protocol #15015004.  All procedures conformed to the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. 
For both mRNA and protein studies of endogenous MT1 expression, wild type and R6/2 
mice were used.  Each sample consists of 5 mice brains pooled.  The resulting material was then 
divided between use for RNA isolation, whole brain protein collection, and isolation of and protein 
collection from synatosomal and non-synaptosomal mitochondria.  Mice were studied at 9 and 12 
weeks of age (mid and late state disease) with an n=3 for each time point (a total of 15 mice per 
age per genotype). 
For study of transgenic MT1 expression, NSE-MT1 and NSE-MT1-R6/2 mice were used.  
Experimental mice where offspring from a cross of female NSE-MT1 transgenic mice [B6CBA-
Tg(NSE-MTNR1A)/Rmf(Pitt)] and R6/2 males [B6CBA-Tg(HDexon1)62Gpb/3J (Jackson 
Laboratory)].  All mice were bred in triads, which increased rates of pregnancy resulting from each 
R6/2 breeder.  CAG length of R6/2 mice was verified for each breeder and animals outside of the 
accepted 150-160 repeat range were excluded from breeding and experiments.  Wild type 
littermates were used during optimization and verification.  Individual mice were used for n=3 per 
genotype, with brains collected at 12 weeks of age. 
3.2.1 Expression at mRNA level 
Whole brain was homogenized in mitochondrial isolation buffer at 4°C.  Total RNA was isolated 
by taking 25μL of this whole brain homogenate for lysis in 500μL TRIzol reagent [Life 
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Technologies, 15596-026] and incubated 5 minutes at room temperature.  100μL of chloroform 
was added, tubes shaken and incubated at room temperature for 3 minutes.  Samples were at 
12,000g for 15 minutes at 4°C and aqueous phase containing RNA transferred.  RNA was 
precipitated with 500μL isopropanol per sample and incubated at room temperature for 10 minutes, 
then centrifuged at 12,000g for 10 minutes at 4°C.  Supernatant was removed and RNA washed in 
75% ethanol before being resuspended in nuclease free water.  RNA was treated with a DNase kit 
[Invitrogen, 18068-015].  After DNase treatment, RNA was purified by incubation with 0.1 
volumes 3M sodium acetate and 3 volumes cold 100% ethanol and incubated overnight at -20°C, 
followed by 30 minute centrifugation at 4°C at 13,000 rpm and two washes with 75% ethanol, and 
finally resuspended in nuclease free water.  RNA quality and quantity were determined using the 
Take3 Micro-volume plate system on Biotek Synergy plate reader.  All isolated mRNA had a 
260/280 ratio of at least 1.8.  Generation of cDNA was using High-Capacity cDNA Reverse 
Transcription Kit [Applied Biosystems, 4368814] following manufacturer instructions.  
QPCR for wild type and R6/2 samples was run using primers for endogenous MT1 mRNA 
[Qiagen PPH02532A-200] using Power SYBR Green PCR Master Mix (Applied Biosystems).  
Reaction volume totaled 15ul and all reactions were run in triplicate.  Reaction mix and cycle 
conditions followed manufacturer protocol. 
QPCR to compare MT1 and MT1-R6/2 samples was run using primers designed to 
specifically detect the transgene.  The forward primer site is within the MT1 portion of the gene 
while the reverse primer site is within the GFP sequence [Forward: 
TGGCCGATAGGGTTAAATGGA, reverse: ACCTTGTCGTCATCGTCTTTG].  These samples 
were run with conditions: 95°C for 5 minutes, followed by 40 cycles of 30 seconds at 95°C and 30 
seconds at 62°C. 
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For all sets, RN18S (housekeeping) was used for normalizing results [forward: 
CGTAGTTCCGACCATAAACGATG, reverse: GCTATCAATCTGTCAATCCTGTCC]. 
Results were read using BioRad CFX Manager software and analyzed by computing 
relating MT1 expression normalized to RN18S according to protocol from Livak and 
Schmittgen105.  NSE-MT1 ΔΔct values were divided by WT to determine fold change; fold 
changes of each sample set were averaged and transformed by normalizing WT to 1.  The same 
process was applied to determine normalized fold changes for NSE-MT1-R6/2 compared to NSE-
MT1. 
3.2.2 Expression at protein level 
The protein levels of endogenous MT1 were assessed in WT vs R6/2 mouse brains. Although the 
cause is unclear, the transgenic MT1 protein in the 2604 MT1 mouse line cannot be detected; for 
the purposes of this dissertation only endogenous MT1 was quantified at the protein level. 
Protein levels of MT1 were assessed in whole brain homogenate and mitochondria 
(nonsynaptsomal and synaptosomal).  Mitochondria were isolated as described in section 2 of this 
dissertation. Whole brain homogenate and isolated mitochondria were incubated with RIPA buffer 
at 5x volume on ice for 30 minutes to lyse tissue. Samples were mixed with 4X SDS sample buffer 
[Boston Bioproducts, BP-110NR] and denatured at 55°C for 15 minutes. All samples were run on 
SDS-PAGE, using a 10% acrylamide gel, then transferred to PVDF membrane [Sigma, 
Immobilon-FL, 05317].  Membrane was blocked using Odyssey blocking buffer [Li-Cor, P/N 
927], incubated with MT1 antibody [Thermo Scientific, PA519109, 1:1,000] and for whole brain 
samples, β-actin antibody [Sigma, A5441, 1:10,000] or for mitochondrial samples, Cox I antibody 
[Santa Cruz, sc-19998, 1:1,000] at 4°C overnight, washed with PBST, and incubated with 
28 
appropriate secondary antibodies [Li-Cor IRDye, 1:30,000].  Blots were scanned on Odyssey CLx 
[Li-Cor] and band intensity quantified using Image Studio software [Li-Cor].  Intensity of each 
MT1 band was normalized by the intensity of respective loading control bands (β-actin for whole 
brain samples, Cox I for mitochondrial samples).  Each R6/2 sample was compared against its 
respective WT sample from the same isolation and preparation to determine fold change.  Fold 
changes for n=3 were averaged to determine final compared differences. 
3.2.3 Statistical analysis 
Analysis of each protein and mRNA pair of values was done using paired t-tests. 
3.3 RESULTS 
 
Figure 3. Endogenous MT1 mRNA expression significantly reduced in R6/2 mice at mid and late stage 
disease.  
Changes in relative expression of endogenous MT1 mRNA shown as the fold change of ΔΔct for WT and R6/2 mice 
at both 9 weeks (left) and 12 weeks (right) of age.  Three biological repeats were used consisting of 5 pooled brains 
each, with each of the three samples run in triplicate.  Expression was normalized by housekeeping gene RN18S, 
then fold differences calculated.  Significant differences at both timepoints determined by paired t-test. 
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Figure 4. Changes in endogenous MT1 protein expression seen in whole brain and mitochondria in R6/2 at 
mid and late stage disease.  
Quantified changes in MT1 protein expression in whole brain and non-synaptosomal (NS) and synaptosonal (Syn) 
mitochondria from WT and R6/2 mice at 9 week (left) and 12 week (right) timepoints.  Three repeats of each sample 
were used, with each sample consisting of 5 pooled brains.  Blots were probed with anti-MT1 antibody and 
appropriate loading control (Β-actin for whole brain samples, Cox I for mitochondrial samples), with blot examples 
shown.  No significant differences were detected at 9 weeks, but whole brain and non-synaptosomal mitochondria 
expression were significantly reduced at 12 weeks of age. 
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Figure 5. Expression of transgenic NSE-MT1 mRNA in NSE-MT1 and NSE-MT1-R6/2 mice at 12 weeks of 
age.   
Three biological repeats were used with each sample run in triplicate.  Expression was normalized by housekeeping 
gene RN18S, then fold differences calculated.  Unpaired t-test showed no significant difference between the two 
(p=0.7564). 
At 9 weeks of age, a reduction in MT1 expression can be seen at the mRNA level, with 
approximately a 40 fold decrease (p=0.046).  At 9 weeks this change in the raw data is not 
significant at the protein level; additionally there are no significant changes in the mitochondrial 
protein level (figure 4).  At 12 weeks of age, mRNA is significantly reduced even further (60% 
decrease, p=0.0004) (figure 3).  Protein is also reduced in 12 week whole brain and non-
synaptosomal mitochondria.  This reduction is not seen in synaptosomal mitochondria (figure 4). 
In mice with transgenic MT1, there is no significant difference in the NSE-MT1 mRNA 
expression with the addition of the R6/2 genotype (p=0.7564) (figure 5). 
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3.4 DISCUSSION 
Previous research within the Friedlander group showed a decrease in MT1 protein expression in 
both whole brain and mitochondria in the extended CAG repeat R6/2 model.  Here, I demonstrated 
that a similar reduction in standard Jax R6/2 mice.  Additionally, I characterized the expression at 
an mRNA level.  The mRNA is decreased at both 9 weeks (mid-stage disease) and 12 weeks (late-
stage disease).  While the protein in mitochondria appears slightly decreased in R6/2 across whole 
brain and mitochondria at 9 weeks of age, this change is not significant until 12 weeks of age, 
where there is a significant decrease in both whole brain and non-synaptosomal mitochondrial 
protein.  Interestingly, I detected no reduction of MT1 in synaptosomal mitochondria. 
Synaptosomal mitochondria are isolated from the active synaptic terminal of neurons.  These data 
may suggest the reduction in MT1 does not severely impact the active functional aspect of neurons; 
however, neuronal death can still be impacted by MT1 reduction elsewhere and receptor-mediated 
melatonin neuroprotection may function there.  Alternatively, reduction of MT1 may increase 
synaptic neuron death or result in die-back of processes reducing the number of synapses overall  
even in the presence of surviving neuron cell bodies, resulting in elimination of synaptosomal 
mitochondria from the sample collected.  Another possible explanation for the unchanged MT1 
expression in synaptosomal mitochondria is the process of isolating these mitochondria may enrich 
healthy mitochondria, resulting in higher detection of MT1. 
These data both verify the effects of the HD phenoytype on MT1 expression and, with the 
addition of the mRNA expression, provide insight that the effect takes place at or before the 
transcriptional level.  No microRNAs known to interact with MT1 are upregulated in HD models, 
but there are many possible other mechanisms which may influence mRNA expression including 
promoter changes or transcriptional dysregulation. 
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The intention of the transgenic MT1 model for this project is to determine if MT1 reduction 
can rescue the R6/2 phenotype.  Therefore it was critical to determine whether the R6/2 phenotype 
affected the expression of transgenic MT1 as well.  With this data, I demonstrate that the R6/2 
phenotype does not appear to affect transgenic MT1 mRNA expressions because the expression in 
the NSE-MT1 mouse alone equals the expression in the NSE-MT1-R6/2 mouse. 
This provides a solid basis for using the NSE-MT1 mouse model crossed with the R6/2 
mouse to determine whether overexpression of MT1 can improve the neuroprotective effects of 
melatonin in that model. 
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4.0    BEHAVIOR AND SURVIVAL 
4.1 INTRODUCTION 
An advantage of the R6/2 model of Huntington’s disease is that it shows progressive motor defects 
that can be characterized by an array of standard mouse behavioral tests106.  While the 
characterization of disease symptoms in mouse models can sometimes be difficult due to the way 
that motor, cognitive, and psychiatric symptoms can interact and overlap, there is a distinct motor 
deficit progression that can be measured in the R6/2 mice44,106.   Various tests are available, but 
one consistently used for R6/2 mice is rotarod.  Critically, fixed speed rotarod was used for the 
initial work showing melatonin’s neuroprotective effects in the R6/2 mouse, and this set of 
experiments aims to repeat that methodology for consistency in both generating and understanding 
outcomes65. 
Because the MT1 transgenic model is newly developed, it was characterized with rotarod 
testing before being used for these experiments, to rule out any effects of the transgene on 
behavioral performance.  The MT1 transgenic performed equally well as wild type littermates 
[personal communication, Amanda Mihalik, University of Pittsburgh].  Additionally, lifespan of 
MT1 transgenics appears to be normal.  Survival studies have not been specifically performed, but 
through colony maintenance within the Friedlander laboratory breeders had a natural survival of 
1-2 years, the typical lifespan for wild type mice of this background. 
For this study, mice were tested on fixed speed rotarod at two speeds.  The higher speed, 
15rpm, is used as an indicator of disease onset, with mice beginning to show decreased latency to 
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fall as motor symptoms first appear.  The lower speed, 5rpm, is used as an indicator of disease 
progression, showing the ongoing progressive decline in motor ability. 
Additionally, this study looks at changes in mouse survival.  Survival time of the R6/2 mice 
has been found to be a good indicator of neuroprotection45. 
The study uses F1 offspring from crosses of R6/2 and MT1 mice.  This cross results in 4 
potential genotypes: NSE-MT1-R6/2 (R6/2+, MT1+), R6/2 (R6/2+, MT1-), MT1 (R6/2-, MT1+), 
and wild type (R6/2-, MT1-).  Mice without R6/2 genotype (including both wild type and MT1 
transgenic) were used as controls for normal performance, but not used for analysis.  The aim of 
this set of experiments was to determine whether an increase in melatonin signaling via the MT1 
receptor will further ameliorate the disease phenotype in R6/2 mice with respect to clinical 
measures. 
4.2 METHODS 
The mice used for this set of experiments were the offspring of NSE-MT1 transgenic [strain 
B6CBA-Tg(NSE-MTNR1A)/Rmf(Pitt)] females, supplied from a colony I bred and maintained, 
and R6/2 males, supplied from our laboratory’s continuously maintained colony.  Due to the 
disease phenotype, female R6/2 mice have very low fertility and we observe when litters are born, 
pups are small, and the females do not care for the pups.  While our R6/2 males also show lower 
rates of fertility compared to WT males, they are still able to generate offspring [personal 
communication, Lisa Ferrando, University of Pittsburgh].  The use of NSE-MT1 females for 
breeding ensured higher pregnancy rates, better litter sizes, and proper care of offspring.  All mice 
were bred in triads, to increase chances of fertilization from each R6/2 male breeder. 
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The R6/2 strain [B6CBA-Tg(HDexon1)62Gpb/3J (Jackson Laboratory)] is a fragment 
model using human exon 1 containing pathogenic CAG repeat length.  In the Friedlander colony, 
this polyglutamine repeat consists of 150-160 tandem CAG repeats.  Repeat length is verified with 
site specific primers (see below) with PCR product run on 1% agarose gel and approximate base 
pair size measured using Invitrogen 50kb ladder [personal communication, Lisa Ferrando, 
University of Pittsburgh].  Mice outside of this range are excluded from breeding and experiments. 
All of the F1 offspring of NSE-MT1 and R6/2 crosses were genotyped at age 15-25 days 
using two sets of primers.  The first was with commonly used R6/2 primers CAG1 and Hu3, also 




Second, the mice were genotyped with a set of transgenic MT1 primers which I designed.  
These primers amplify a section of the transgene which spans from the MT1 to GFP portions, 




Previous work has shown no difference in behavioral measures between male and female 
R6/2 mice45.  For this experiment, I used all female mice because males were used for mouse 
colony maintenance.  After genotyping, I weaned mice directly into their experimental cohorts 
with 4-5 mice per cage.  A significant enrichment effect has been seen in the R6/2 mice when 
mutants are housed with wild type107.  In order to avoid confounding due to this effect, all mice 




I began melatonin treatment of 30mg/kg at 30 days of age and continued until death.  The dose 
was chosen after preliminary experiments using 30, 50, and 100mg/kg doses demonstrated 
30mg/kg to be a saturating concentration in R6/2 mice.  Mice received intraperitoneal injections 
daily with a total injection volume of 100μl.  Injection sites alternated between left and right sides 
of body each day to decrease irritation.  Melatonin (Sigma, M5250) is not soluble in water/saline.  
The melatonin was first dissolved in DMSO and vortexed briefly; DMSO volume was calculated 
to 3% of total solution volume.  Once melatonin was fully dissolved, PBS was added to bring the 
solution to its final volume. 
Because daily handling and injection can cause stress in these animals and alter disease 
phenotype, control groups were also injected daily with 100μl vehicle. 
Eight cohorts consisted of the following genotypes and treatments: 
R6/2 mutant + MT1 mutant (melatonin; vehicle) 
R6/2 mutant only (melatonin; vehicle) 
MT1 mutant only (melatonin; vehicle) 
Wild type (melatonin; vehicle) 
4.2.2 Behavior analysis 
Previous studies by the Friedlander group on R6/2 mice have used fixed speed rotarod 65.  The 
behavior measures for this aim were consistent with this in order to generate comparable data and 
allow for analyzing similarities or differences in trends with earlier characterizations of these mice.  
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The rotarod system (Columbus Instruments) measures active behavior, yielding results that 
indicate coordination, strength, and endurance.  Each mouse was trained at 5 weeks of age on the 
fixed speed rod at 15rpm until able to complete a 7 minute trial without falling.  Any mice unable 
to adequately perform during training were removed from test groups.  Trial testing consisted of 
placing a mouse on the constant speed rotarod at 15rpm and 5rpm for 7 minutes each; mice are 
given three attempts to complete the trial without falling, with a minimum 10 minute rest between 
attempts.  The best time from these three attempts was used for analysis.  Mice who died before 
the end of rotarod trials were recorded at 0 minutes; these mice were not censored from the 
experiment to avoid weighting the average time towards longer living mice. 
4.2.3 Survival 
The same mice used for behavioral testing were also used for survival analysis.  I monitored the 
mice daily and counted end of survival as either death or a mouse’s inability to right itself within 
30 seconds of being placed on its back, consistent with previous R6/2 work45. 
4.2.4 Statistical analysis 
Rotarod times were compared week by week using Friedman's 2-way non-parametric ANOVA to 
compare timepoints between grouped cohorts (saline treated R6/2 and NSE-MT1-R6/2 compared 
to melatonin treated R6/2 and NSE-MT1-R6/2), which indicated significant differences between 
melatonin and saline treatments, starting at 10 weeks of age for 15rpm and 11 weeks of age for 
5rpm.  Kruskal-Wallis tests were used to compare timepoints between individual cohorts (separate 
genotypes and treatments): melatonin treated R6/2 with melatonin treated NSE-MT1-R6/2. A GEE 
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repeated measure analysis was used to analyze rotarod times as a whole for overall trends.  
Assistance in choice and performance of these statistical tests was provided by Yuefang Chang, 
PhD of the Department of Neurological Surgery. 
The survival for R6/2 positive groups was compared using a log-rank test.  Follow-up log-
rank tests were used to evaluate the differences between melatonin and saline treatments for each 
genotype, using a Bonferroni-corrected threshold for determining p value significance 
(threshold=0.0083).  
4.3 RESULTS 
In order to establish the melatonin dose to be used for this set of experiments, I first tested 30, 50, 
and 100 mg/kg doses by injection.  I found that in open field measurements of R6/2 performance, 
increased dose provided no improved protection, indicating 30mg/kg to be a sufficient saturating 
dosage.  In addition, I found that while open field behavioral testing provided sufficient data to 
assess dosage, its outcomes were not comparable to the previously established rotarod protocol in 
the Friedlander laboratory; thus rotarod was used for subsequent studies. 
Given three trials at each speed, the best time for each mouse was used for analysis.  Times 
for each cohort were averaged.  At 15rpm (figure 6), the speed indicating disease onset, the groups 
receiving saline treatment performed poorer than those receiving melatonin treatment (p<0.0001).  
Of the groups receiving melatonin, the raw data suggests that the NSE-MT1 transgenic performed 
better starting at 10 weeks; however the difference between the R6/2 melatonin treated and the 
NSE-MT1-R6/2 melatonin treated is only significant at 13 weeks (p=0.004).  Both individual 
timepoints and overall trend were compared.  While melatonin treated NSE-MT1-R6/2 was 
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significantly improved at the 13 week timepoint compared with melatonin treated R6/2, when the 
cohorts are analyzed as a whole, they are not significantly different (p= 0.180). 
 
Figure 6. Time on rotarod at 15rpm for R6/2 cohorts, +/- MT1 transgene, +/- melatonin injection.  
Mice were placed on the rod for trials of 7 minutes total with 3 attempts to pass.  The maximum time each mouse 






Figure 7. Time on rotarod at 5rpm for R6/2 cohorts, +/- MT1 transgene, +/- melatonin injection.   
Once cohorts failed the full 7 minutes for 15rpm, they were additionally tested at 5rpm.  Mice were placed on the 
rod for trials of 7 minutes total with 3 attempts to pass.  The maximum time each mouse stayed on the rod during the 
three trials was recorded.  Performance at 5rpm is indicative of disease progression. 
 
At 5rpm (figure 7), the speed indicative of disease progression, a similar trend is seen as at 
the higher speed.  The mice receiving melatonin treatment performed much better than those 
receiving only vehicle (p<0.0001).  However, the difference between R6/2 with melatonin 
treatment and NSE-MT1-R6/2 with melatonin treatment is small.  This difference is significant at 
14 weeks (p=0.0003), but no other timepoints.  The overall trend for these groups shows no 
significant difference (p=0.150). 
 
Table 1. Summary table of average survival (days) for each cohort ± standard deviation. 
 Saline Melatonin 
R6/2 97.0 ± 8.9 108.5 ± 5.8 
NSE-MT1-R6/2 99.0 ± 9.0 112.0 ± 9.2 
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These mice were also assessed for survival (figure 8).  Survival analysis showed a 
significant difference in median age of death (summarized in table 1) between saline vs melatonin 
treatment (p<0.0001 for NSE-MT1-R6/2 genotype, p=0.0028 for R6/2 genotype) but there is no 
significant difference between melatonin treated R6/2 vs NSE-MT1-R6/2 (p=0.1053). 
 
4.4 DISCUSSION 
As seen in previous work within the Friedlander laboratory, melatonin was beneficial in both 
behavioral measures and survival in the R6/2 mice65.  However, contrary to the initial hypothesis, 
the behavior and survival in these melatonin treated R6/2 mice was not further extended with the 
Figure 8: Survival of R6/2 mice +/- NSE-MT1 genotype, +/- melatonin treatment.  
 Survival was observed for the same cohorts of mice used in rotarod testing.  Survival was defined as death or 
mouse’s inability to right itself within 30 seconds when placed on its back. 
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addition of MT1 overexpression.  This result lends itself to several possible explanations which 
warrant potential further investigation. 
4.4.1 Molecular influences 
While cellular models indicated that melatonin neuroprotection was mediated through MT1, it is 
possible that in an in vivo chronic model of Huntington’s, this protection may be affected by the 
chronic nature of the in vivo model, supplemented by an alternate mechanism, or modified through 
a regulatory mechanism. 
Cellular models testing the mechanism of melatonin’s neuroprotection studied an acute 
stress.  Additionally, this MT1 overexpression transgenic has shown to additively protect against 
neuronal death in models of stroke [manuscript in preparation].  The stroke model represents 
another acute injury.  Melatonin’s neuroprotection appears to be primarily mediated by MT1 in 
such acute models; however, the MT1 mediated protection may not be the primary mechanism in 
a chronic model. 
In this chronic model, the receptor-mediated mechanism of melatonin may be 
supplemented by melatonin’s role as an antioxidant.  In post-mortem human HD brains, several 
markers of oxidative stress are elevated108; a similar pattern is seen in the R6/2 model mouse as 
well47.  The cellular damage caused by increased free radicals and oxidative stress may be a 
contributing factor to the HD phenotype.  Therefore, melatonin’s additional role as an antioxidant 
may confound these results investigating receptor-mediated protection.  Melatonin may function 
as a neuroprotectant through both antioxidant and receptor signaling pathways, rather than MT1 
alone. 
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Melatonin dosing may be another factor for understanding the experimental outcomes seen 
here.  The melatonin dosage for these experiments was determined using R6/2 mice.  This 
established 30mg/kg as a saturating dose for the R6/2 mouse model.  However, because the dosage 
was not determined in the NSE-MT1-R6/2 mouse, we cannot be sure the 30mg/kg dose is 
saturating with the additional MT1 expression.  If the melatonin was not saturating in these mice, 
we would not be able to see the full protective effect of melatonin with overexpressed MT1. 
Finally, in discussing the biological function of MT1, it is vital to address the role of 
GPR50.  GPR50, as a melatonin receptor-like G protein, is able to dimerize with MT1.  This 
dimerization results in a significant reduction in MT1 signaling.  While the function of GPR50 is 
yet undiscovered, it may play a role in regulating melatonin signaling.  In the context of this work, 
it may affect the functionality of the transgenic MT1, reducing the overall impact of the 
overexpression. 
4.4.2 Mouse model influences 
While these results may indicate a number of possible outcomes regarding melatonin’s mechanism 
of action and the role MT1 plays in neuroprotection, I must also consider that the results may be 
due to the model itself.  While the transgenic MT1 has been detected to be overexpressed at the 
mRNA level [personal communication, Amanda Mihalik, University of Pittsburgh], the transgenic 
protein itself has been particularly difficult to detect and characterize.  Ongoing work indicates 
that while it is overexpressed, the fold increase may be lower in the 2604 line used for these 
experiments compared to the second founder line, 2606. 
As a result, this particular line of transgenic MT1 mice may not overexpress the receptor 
at a high enough level to effect significant change at a behavior or survival level.  The ideal solution 
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to this potential flaw in the MT1 mouse model is to use a line with higher transgenic expression.  
The Friedlander laboratory maintains a second MT1 line from a second founder, which has shown 
higher mRNA expression as well appearing to have increased protein expression.  However, 
consistent with studies which have shown MT1’s impact on reproductive cycles and hormones68,73, 
these mice breed very poorly, taking an extended period of time to generate pregnancies, with 
resulting litter sizes of only two to three pups.  Pairing this very poor breeding line with the poor 
breeding R6/2 line was not considered feasible to generate significantly sized cohorts for such a 
study as this. 
Further studies may benefit from additionally looking at the effects of MT1 knock-
down/out.  Several MT1 knockout (KO) lines have been developed, primarily for use in studying 
circadian rhythm.  If the proposed mechanism is correct and the inability to detect significant 
behavioral changes is indeed due to the NSE-MT1 model itself, I would expect that R6/2 positive, 
MT1 KO crossed mice would produce a dramatically more severe phenotype, unable to be rescued 
by treatment with melatonin. 
While this work is not feasible within the scope of this dissertation project, it represents an 
important follow-up experimental design when it comes to understanding molecular mechanisms 
when using genetic mouse models.  MT1 KO lines are currently available commercially. 
A second potential limitation of these mouse models is the rapid disease progression and 
short lifespan of the R6/2 mouse.  R6/2 was the first HD mouse model developed47; however, it 
has its limitations as a model, most notably being a fragment and not full length model and being 
a very rapid and severe model of disease onset and progression, which led to the development of 
a plethora of other HD model mice109.  R6/2 continues to be a widely used model, with over 500 
publications to date using it, and it is a valuable tool for understanding the pathology of HD.  
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However, the behavior and survival data shown here indicate that with MT1 overexpression effect 
being seen only at very late timepoints (13-14 weeks), the mice may die before a significant effect 
can be observed. 
The highest CAG repeat lengths in human HD are seen in juvenile HD, which typically has 
60+ repeats110.  With 150-160 repeats, the R6/2 model is markedly more severe.  The R6/2 model 
in fact has the longest CAG repeat length of any HD mouse model and by far the shortest 
lifespan109.  This short and severe phenotype is beneficial for extensive studies with a rapid 
turnover of animals with relatively little variability in survival.  However, it may best be 




5.0    CASPASES AND HISTOLOGY 
5.1 INTRODUCTION 
The R6/2 mouse is noted for having progressive behavioral and neuropathological symptoms, a 
key feature that makes it an important model of HD.  Changes between wild type and R6/2 mice 
can be seen as early as postnatal day 1, when huntingtin aggregates can first be detected in the 
neostriatum.  However, most striking changes in neuropathology are not seen until later in the 
disease.  Notable changes seen in the brain include an overall reduction in brain weight and 
volume, gross enlargement of lateral ventricles, neuronal atrophy, and presence of huntingtin 
aggregates45.  These changes progress in severity over the course of the disease.  Behavioral 
deficits, such as decreased performance on rotarod, correlate with histological markers such as the 
presence of huntingtin aggregates and changes in neuronal density111.  Neuronal atrophy is a 
hallmark of the disease and can be quantified as a reduction in both size and number of neurons in 
the striatum45.  In 12 week R6/2 mice, striatal neuronal count is reduced as much as 50% compared 
with wild type mice112. 
The pathology of HD is complex, and in addition to these known neurological 
characteristics, recent research highlighted the particular role apoptosis plays in 
neurodegeneration, indicating a possible mechanism for the damages caused by this 
disease30,113,114.  Apoptosis, or programmed cell death, is characteristic of neurologic disease115.  It 
is the primary form of cell death in neurodegenerative diseases, seen as a mechanism of neuron 
death in diseases such as Alzheimer’s, stroke, and ALS30. 
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Apoptosis results from a biochemical cascade. Early in this cascade, caspases are activated; 
these then eliminate molecules used to maintain cell survival115.  The cascade causes cell structures 
condensation, the mitochondrial aggregation, and chromatin condensation.  The cell fragments 
after its death and condensed chromatin is cleaved30,115.  Apoptosis is the result of a complex 
interplay of molecular components. 
Cysteine-dependent aspartate specific proteases (caspases) are primary factors in 
apoptosis.  The caspase family is named for caspase 1, or interleukin-1β-converting enzyme16.  
Since its discovery, a total of 11 caspases have been identified in humans.  The molecules begin 
as procaspases, which contain a recruitment domain at the N-terminal16.  The type of recruitment 
domain helps indicate where in the apoptotic cascade a caspase functions.  Caspases can function 
upstream or downstream within the cascade, initiating or executing, respectively.  The N-terminal 
domain of most upstream molecules (procaspases 1, 2, 4, 5, 9, 11, 12, 13) is a caspase-recruiting 
domain (CARD).  There are also two caspases (8 and 10) which have a death-effector domain 
(DED) at the N-terminus.  These upstream caspases function to initiate the process of apoptosis.  
The other caspases (3, 6, 7, 14) have a short prodomain30.  These caspases function in actual 
executing of the cell by both destroying cellular structures and degrading DNA16 
In the R6/2 model of HD, the activation of caspases is known to play a critical role in 
disease progression with specific chronology of activation35. The activation of caspases 3 and 9 is 
noted to occur later in disease, while activation of caspase 1 occurs earlier35,41.  Caspase 1, which 
acts upstream of the mitochondria, acts by cleaving Bid; the cleavage product (tBid) the localizes 
to the mitochondrial membrane where it effects the release of cytochrome c35.  Cytochrome c 
initiates the caspase mediated apoptotic pathway downstream of the mitochondria.  Previous work 
explored the ability of melatonin to inhibit cell death pathways; notably melatonin is able to inhibit 
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the activation of caspase 1 and caspase 3 and prevent cytochrome c release in both ALS and HD 
mouse models65,100.  
To further assess the role of MT1 in this melatonin mediated neuroprotection, I conducted 
experiments to determine whether overexpression of the receptor would further inhibit the 
activation of caspases and to assess neuronal atrophy via both neuronal count in wild type, R6/2, 
and NSE-MT1-R6/2 mice treated with saline or melatonin. 
5.2 METHODS 
Mice were treated and collected as described in section 3 of this dissertation.  Mice tested for 
caspase activation consisted of wild type, R6/2, MT1, and NSE-MT1-R6/2 mice with both saline 
and melatonin treatment groups at 9 and 12 weeks of age.  Neuronal counts were measured in 
control (wild type treated with saline) and R6/2 and NSE-MT1-R6/2 mice treated with saline and 
melatonin at 12 weeks of age, n=4 for each group. 
5.2.1 Caspase activity assays 
Previous work by the Friedlander group used fluorometric assays to assess caspase activity with 
high sensitivity35.  Therefore, caspase activation in brains of these mice was also measured using 
fluorometric assay kits for caspases 1, 3, and 9 [Abcam, ab39412, ab39383, and ab65607, 
respectively].  These fluorometric kits used caspase specific substrates (YYAD-AFC, DEVD-
AFC, and LEHD-AFC for 1, 3, and 9, respectively) which emit a blue light (400nm wavelength) 
when uncleaved and, when cleaved by their respective caspase free AFC (7-amino-4-
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trifluoromethyl coumarin), which emits fluorescence (excitation 400nm, emission 505nm).  
Caspase activity is quantified by amount of free AFC produced. 
While the kits were designed for use with cells, I adapted a protocol for use with mouse 
brain tissue from the manufacturer instructions, correspondence with manufacturer, and direct 
optimization: a half brain was homogenized in 700μL of kit lysis buffer and spun at 1000rpm for 
5 minutes at 4°C to remove debris.  From this, 500μg protein (total volume 50μL in lysis buffer) 
was combined with 50μL kit reaction buffer (containing 10mM DTT) and 5μL of 1mM substrate 
(caspase 1, 3, or 9 substrates, from kit).  Plates of samples were incubated at 37°C for 2 hours and 
read on Synergy H1 with read settings described in kit protocol.  Outputs were calculated as fold 
increase compared to control (wild type untreated sample). 
5.2.2 Tissue collection and preparation 
For neuropathology assessment, mice were treated and collected as described in section 4 of this 
dissertation.  Mice tested consisted of control (wild type treated with saline) and R6/2 and NSE-
MT1-R6/2 mice treated with saline and melatonin.  For each measurement, a total of 4 mice were 
used. 
Brains were collected at 12 weeks of age (late stage disease).  Mice were cardiac perfused 
with approximately 60ml of 10% formalin.  After perfusion, brains were collected and stored in 
10% formalin at 4°C for 24 hours.  Brains were then transferred to increasing concentrations of 
glycerol (10% followed by 20%).  They were stored at 4°C in the final 20% glycerol solution until 




Sections were stained with cresyl violet (5 minutes xylenes, 5 minutes 100% ethanol, overnight 
95% ethanol, 5 minutes 70% EtOH, 5 minutes ddH2O, 10 minutes cresyl violet, 5 minutes ddH2O, 
5 minutes ddH2O, 5 minutes 70% EtOH, 5 minutes 95% EtOH, 5 minutes 95% EtOH, 5 minutes 
100% EtOH, 30 sec 100% EtOH, 1 minutes xylenes) and analyzed for neuronal cell counts using 
Image-J software.  For each mouse (n=4) sample, a total of 5 images were collected and the counts 
averaged. 
5.2.4 Statistical analysis 
Statistical analysis of caspase activation and neuronal counts was done using a 2-way ANOVA 
with Tukey’s multiple comparisons test, generating multiplicity adjusted p-values for each 
cohort’s comparison. 
5.3 RESULTS 
Caspase 1, 3, and 9 activity was assessed in age 9 weeks and 12 weeks mice using fluorometric 
assays and fold changes of activity were determined in comparison to untreated WT mice. For all 
caspases and timepoints, a significant difference can be seen between untreated WT and untreated 
R6/2, indicating the test is sensitive enough to detect the activation of these caspases (figure 9).  
With no significant difference for any timepoint of any caspase for untreated R6/2 vs untreated 
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NSE-MT1-R6/2, it can be seen that the addition of the MT1 transgenic receptor alone has no 
beneficial effect in these mice without the presence of melatonin. 
At 9 weeks, an impact of treatment can only be seen with caspase 3 (figure 9c), where the 
decrease in activity is seen with the addition of treatment in the R6/2 genotype (p=0.007).  At 12 
weeks, impact of addition of melatonin to the R6/2 shows significant decreases in all three caspases 
(figure 9b, d, f).  This is consistent with previous findings that show melatonin ameliorates disease 
phenotype, including caspase activation. 
At 9 weeks, the treated NSE-MT1-R6/2 genotype appears to decrease caspase activation 
more strongly than treatment confers to R6/2 genotype alone (figure 9a, c, e), although this trend 
is not significant at the 9 week timepoint.   
However, at 12 weeks, this difference becomes significant for caspases 3 and 9 (p<0.0001 
and p=0.011, respectively) (figure 9d and f), indicating that addition of MT1 strengthens the 
protective effects of melatonin treatment.  However, this improvement appears very late in the 
disease (near the end of lifespan for the R6/2 model), and it appears not to produce a strong enough 




Figure 9. Caspase 1, 9, and 3 activity in WT, NSE-MT1, R6/2, and NSE-MT1-R6/2 mice, treated with saline 
or melatonin.  
 Caspase  activation in whole brain homogenate was determined using fluorogenic assays.  Activation is shown as 
fold change from saline treated wild type.  For each sample group, n=3 with individual samples run in triplicate.  
Activation was assessed at mid-stage (9 weeks) and late-stage (12 weeks) of disease.  Notable significance is 
indicated with asterisks (*: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001). 
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Table 2. Summary of p values for all comparisons of caspase activation between genotypes and treatments at 
9 and 12 weeks of age. 
    saline melatonin 













































WT 0.9991 <0.0001 <0.0001 0.5385 >0.9999 <0.0001 <0.0001 
NSE-MT1  <0.0001 <0.0001 0.8563 >0.9999 <0.0001 <0.0001 
R6/2   >0.9999 0.0006 <0.0001 >0.9999 0.9993 




WT     0.7177 0.0006 0.0023 
NSE-MT1      <0.0001 <0.0001 






WT >0.9999 <0.0001 <0.0001 0.9984 >0.9999 <0.0001 <0.0001 
NSE-MT1  <0.0001 <0.0001 0.9990 >0.9999 <0.0001 <0.0001 
R6/2   0.9990 <0.0001 <0.0001 <0.0001 <0.0001 




WT     0.9886 <0.0001 <0.0001 
NSE-MT1      <0.0001 <0.0001 











WT >0.9999 <0.0001 <0.0001 >0.9999 0.9988 <0.0001 0.0006 
NSE-MT1  <0.0001 <0.0001 >0.9999 .9963 <0.0001 0.0008 
R6/2   0.5896 <0.0001 <0.0001 0.7777 0.0486 




WT     0.9971 <0.0001 0.0007 
NSE-MT1      <0.0001 0.0001 






WT 0.9997 <0.0001 <0.0001 0.9997 0.8424 <0.0001 <0.0001 
NSE-MT1  <0.0001 <0.0001 >0.9999 0.9794 <0.0001 <0.0001 
R6/2   0.6084 <0.0001 <0.0001 <0.0001 <0.0001 




WT     0.9777 <0.0001 <0.0001 
NSE-MT1      <0.0001 <0.0001 











WT 0.9998 <0.0001 <0.0001 0.9988 0.9977 0.0005 0.0004 
NSE-MT1  <0.0001 <0.0001 0.9636 0.9511 0.0016 0.0013 
R6/2   0.1190 <0.0001 <0.0001 0.0007 0.0009 




WT     >0.9999 0.0001 0.0001 
NSE-MT1      0.0001 <0.0001 






WT 0.9994 <0.0001 <0.0001 0.9995 0.9462 <0.0001 <0.0001 
NSE-MT1  <0.0001 <0.0001 >0.9999 0.9986 <0.0001 <0.0001 
R6/2   0.9722 <0.0001 <0.0001 <0.0001 <0.0001 




WT     0.9983 <0.0001 <0.0001 
NSE-MT1      <0.0001 <0.0001 




Figure 10.  Representative images of neuronal density and number in striatum of WT, R6/2, and NSE-MT1-
R6/2 mice, treated with saline or melatonin.   
Neuronal counts, an indication of neuronal cell death, were assessed in striatum of 30μm brain sections stained with 
cresyl violet (Nissl stain). 
 
As expected, neuronal number was significantly decreased in the striatum of saline treated 
mice with the R6/2 genotype compared to WT, with the number reduced by 42.7% in R6/2 
compared with WT (p=0.0007) and 37.6% in NSE-MT1-R6/2 compared with WT (p=0.0019).  
This reduction was ameliorated by treatment with melatonin.  In the NSE-MT1-R6/2, treatment 
with melatonin significantly increased neuronal number by 27.2% (p=0.0442).  While there were 
consistently higher counts in the NSE-MT1-R6/2 melatonin treatment compared to R6/2 melatonin 




Figure 11. Neuronal counts from WT, R6/2, and NSE-MT1-R6/2 treated with saline or melatonin. 
Neuronal number in each section was analyzed with ImageJ. Quantification is the average of 5 image sections per 
brain, n=4 brains per genotype/treatment.  Significance is indicated with asterisks (ns: no significance, *: p<0.05,**: 
p<0.01). 
5.4 DISCUSSION 
While the NSE-MT1-R6/2 genotype did not show significant improvement in rotarod performance 
or survival, significant changes in caspase activation were detected.  While it is possible the R6/2 
phenotype is too aggressive to see macro changes at the level of behavior and survival, I 
determined to assess whether the differences in caspase activation were able to still make subtle 
changes at the neuronal level.   
Treatment with melatonin resulted in significant reduction of caspase activation in the 
diseased mice.  This finding is consistent with previous work indicating that melatonin is able to 
reduce neuronal cell death.  The ability of melatonin to reduce caspase activity, and for this effect 
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to be strengthened by the addition of the MT1 transgenic, illustrates that MT1 does play an 
important role in mediating melatonin neuroprotection.  Similar to the results seen with behavior 
and survival, this effect shows up very late in the disease and appears not to provide a strong 
enough biological impact to prolong survival or alter disease course.  This data, in combination 
with the outcomes seen with behavior and survival, provides a more complete picture of the roles 
of MT1 in melatonin neuroprotection, although there are still multiple potential conclusions to be 
explored further. 
The inability of this caspase activity rescue to significantly impact the disease course at a 
macro level (i.e. behavior and survival) may be in part due to the aggressive nature of the R6/2 
HD phenotype, as mice begin dying before a significant effect takes place.  The R6/2 model of HD 
is indeed one of the fastest and most aggressive models available to study the disease.  While the 
model has the advantage of also being among the most consistent in terms of its onset and 
progression timeline, this also results in an early death.  While the protective effect of melatonin 
itself can be clearly seen within the lifespan of the mouse, amelioration due to the addition of the 
MT1 overexpression may not be additionally strong enough to elicit an outcome within the 
mouse’s lifespan.  A clearer result may theoretically be possible by using a slower progressing 
model or a greater overexpression of MT1.  The latter option seems less feasible as our higher 
expressing model of the MT1 transgenic (the 2606 line) displays significant issues in breeding.  
Due to time constraints and mouse availability, experimentation with an alternate HD model 
mouse or the higher expressing MT1 line were not pursued for this project, but remain a potential 
path for future study. 
In addition to the caspase activation data, neuronal counts provide key insight into the 
subtle changes the NSE-MT1-R6/2 genotype provided when combined with melatonin treatment.  
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The changes at the cellular level shown here follow the pattern of changes seen with caspase 
activation and rescue, although with a milder effect.  This slight perceived difference continues to 
be seen at the behavioral level, with the effect again being even more mild (non-significant).  The 
neuropathological data provides a connecting line between understanding the role of 
neuroprotection against apoptotic factors and an overall alteration in behavior and survival.  
However, the MT1 overexpression ultimately did not provide a strong additive effect to the 
administration of melatonin alone. 
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6.0    CONCLUSIONS & DISCUSSION 
HD is a devastating disease with no known cure or treatment.  Finding mechanisms of its pathology 
as well as mechanisms of protection are critically important to helping individuals and families 
with this disease. 
Melatonin has been widely studied in a variety of roles, including in circadian rhythms, as 
an antioxidant, and most recently as a neuroprotectant.  While melatonin is known to improve 
outcomes for other neurodegenerative diseases such as Parkinson’s and Alzheimer’s, its ability to 
ameliorate symptoms in HD is a promising new development.  In order to fully investigate the 
neuroprotective effects of melatonin, we must develop a clear picture of the mechanisms of 
melatonin’s function within cells.  Because melatonin functions in cells through multiple 
mechanisms, including both antioxidant and receptor mediated roles, understanding how these 
functions contribute to its neuroprotective properties allows us to direct efforts to maximize 
neuroprotection as we aim to develop treatments for individuals with HD. 
Melatonin signaling occurs via two receptors, MT1 and MT2.  Because the neuroprotective 
effects of melatonin occur through MT1, it is the focus of this research.  The Friedlander laboratory 
previously found MT1 is located on the mitochondria.  Melatonin’s highest concentration within 
the cell is also the mitochondria, although the mechanism of melatonin’s mitochondrial 
localization was unclear.  The Friedlander group identified the two terminal enzymes involved in 
melatonin synthesis, AANAT and ASMT, as being localized to the mitochondria, pointing to the 
possibility of their function being carried out there.  Here, I demonstrate isolated mitochondria are 
capable of synthesizing melatonin from serotonin.  This centralizes mitochondria in understanding 
the mechanisms of melatonin’s neuroprotection via MT1.  This also establishes a novel autocrine 
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loop for the synthesis and signaling of neuronal melatonin.  Melatonin is synthesized in 
mitochondria, where is binds to its MT receptors.  Melatonin does not need to be transported within 
the cell or from external sources in order for rapid signaling to occur.  No other known autocrine 
signaling in the mitochondria is documented in literature.  Ongoing studies are aimed at examining 
how this melatonin synthesis in the mitochondria may be affected by the HD phenotype, using the 
R6/2 mouse model. 
The relationship between mitochondria and HD is well documented.  While there are many 
theories as to the precise role the mitochondria plays in HD pathology, it is clear that many 
functions of the mitochondria, from protein import to caspase mediated cell death to antioxidation, 
are affected in HD.  Knowing melatonin synthesis and melatonin’s signaling via MT1 both occur 
in the mitochondria, I sought to determine whether MT1 may also be affected by HD.  Previous 
work with an R6/2 model with longer CAG repeat length showed MT1 expression decreased.  My 
experiments sought to determine whether this downregulation occurred in the standard R6/2 mouse 
model, with approximately 144 CAG repeats.  Indeed MT1 is downregulated in this R6/2 line at 
both an mRNA and protein level, seen at mid-stage disease and progressing to a larger significant 
difference by late stage disease.  Not only does the HD phenotype decrease MT1 decrease but it 
does so in a progressive fashion correlating with disease progression.  As previous research 
indicated MT1 as the mechanism of melatonin’s neuroprotection, this decrease suggests the 
downregulation of MT1 contributes to increased neuronal death as the disease progresses. 
The NSE-MT1 mouse model was developed to explore the effects of increased MT1 
signaling.  This increase can ameliorate the effects of decreased MT1 expression in an HD model 
such as the R6/2 and increase the efficacy of neuroprotection with melatonin.  R6/2 and NSE-MT1 
mice were crossed to create NSE-MT1-R6/2 offspring.  I tested whether the decrease in 
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endogenous MT1 expression was paralleled with transgenic MT1.  While the mechanism by which 
R6/2 downregulates endogenous MT1 is unknown, it may act through mechanisms such as 
transcriptional regulation, DNA modification, or mRNA degradation.  These mechanisms could 
potentially affect the transgenic MT1, preventing an effective increase in MT1 expression in the 
NSE-MT1-R6/2 model.  I found transgenic MT1 mRNA expression was the same with and without 
the addition of the R6/2 genotype at late stage disease (12 weeks).  This provided a solid rationale 
for using the cross mice for experiments with melatonin neuroprotection; the increased transgenic 
MT1 compensates for the loss of endogenous MT1 in the R6/2 model without itself being reduced 
by the disease phenotype.  Additionally, with the transgenic unaffected but endogenous decreased 
in R6/2, possible mechanisms of the latter can be posited.  NSE-MT1 contains the human MT1 
gene; while similar and homologous to the mouse MT1, it is not identical.  While a search of the 
database GEO found no known microRNAs which target MT1 and are upregulated in R6/2 mice, 
factors such as changes to transcriptional regulators may affect endogenous mouse MT1 in a site 
specific way.  Additionally, and potentially more likely an explanation, the endogenous and 
transgenic MT1 have different promoters, which may play a role in how the HD phenotype affects 
each due to HD affecting the endogenous MT1 promoter via changes in enhancers or 
transcriptional regulators.  Mutant HTT is known to interfere with transcription factors and 
transcriptional proteins, cause histone and methylation based regulation of DNA, and alter miRNA 
expression.  The results of these experiments opens a new understanding of how the HD 
phenotype, as seen in the R6/2, may affect melatonin signaling via MT1.  In a broader scheme, 
insight into how HD downregulates MT1 expression may be useful in understanding HD’s many 
gene regulation effects. 
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Because the transgenic MT1 is not affected by the R6/2 genotype, it has the potential to 
rescue the loss of melatonin signaling via MT1 and increase the neuroprotective effects of 
melatonin.  The R6/2 and NSE-MT1 mice were crossed to investigate the capability of increased 
MT1 expression to improve melatonin's previously seen amelioration of the disease phenotype. 
At a molecular level, melatonin is able to inhibit cell death via caspase-mediated pathways, 
although the specific molecular mechanism responsible is unknown.  The overexpression of MT1 
produced a modest but significant improvement on reduction of caspase activation, particularly at 
late-stage disease.  This demonstrates that a potential pathway for melatonin signaling via MT1 to 
prevent activation of cell death pathways.  However, further experiments to examine the effects of 
this at a macro level were less conclusive.  While cell death via caspase-mediated pathways appears 
decreased, cell death may still be occurring via other pathways.  In order to assess whether this 
reduction in caspase activation was truly protective from cell death, an assessment of neuronal 
death was needed.  Neuronal counts suggested improvement with the addition of the transgenic 
MT1 but were still statistically decreased compared to controls.  Similarly, the measures of disease 
onset and progression using rotarod testing suggested an improved phenotype in the NSE-MT1-
R6/2 compared to R6/2 alone, however these rotarod measures only conclusively demonstrated 
improved at very late stage disease.  As with other endpoint measures, data suggested but could 
not conclusively demonstrate improved survival.  While caspase activation was further decreased 
in melatonin treated NSE-MT1-R6/2 compared to R6/2 alone, reducing caspase-mediated cell 
death, the data do not suggest this decrease is sufficient to decrease neuronal cell death and 
ameliorate the disease phenotype.  There are several possible explanations for this outcome 
including choice of mouse models, feedback mechanisms, modification of MT1 signaling 
functions, alternative pathways of neuroprotection, or insufficient melatonin dosing. 
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With improved outcomes seen primarily in late stage disease, there is the possibility that 
the mice die before a strong and significant effect of the neuroprotection can be seen.  While the 
R6/2 model is advantageous for its robust disease phenotype and clear progressive pathology, it 
also has the disadvantage of being a particularly aggressive and quick model.  As a result, the 
effects of MT1 overexpression may have been more difficult to see at a macro phenotypic level.  
The use of a slower disease model in future work may allow for seeing a stronger effect of MT1 
overexpression. 
Also factoring in to the efficacy of the mouse models is the possibility that transgenic MT1 
expression may not have been high enough.  Of the two founder lines for the NSE-MT1 mouse 
model, the line used for this work, line 2604, had lower expression of the transgenic MT1 
compared to the second founder line 2606.  Future work in the understanding of increased 
melatonin signaling via MT1 may require use of the higher expressing line with the aggressive 
R6/2 phenotype.  Additionally, research exploring melatonin's neuroprotection as it functions 
through MT1 would benefit from pairing both overexpressed MT1 models and knockout MT1 
models with HD mouse modeling.  Given the slight improvements in disease phenotype with the 
addition of excess MT1, one would expect to see all melatonin-related neuroprotection eliminated 
with the knockout of MT1. 
Conversely, it is possible that transgenic MT1 expression was high, but the melatonin dose 
was not optimal.  While the melatonin dosage was optimized to be a saturating level in the R6/2 
mouse, the dose given may not have been saturating for the increased amount of MT1.  In future 
studies, dosing should be determined for the overexpressed MT1 levels, allowing for a level of 
melatonin which would fully saturate the transgenic MT1 and maximize increased signaling via 
MT1.  Alternatively, no lower doses were tested during optimization and it is possible the dose of 
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melatonin is sufficient to result in saturating downstream signaling, such that an increased number 
of receptors would not affect the already saturated signaling pathway. 
The expression of endogenous MT1 may be affected by transgenic MT1 expression via a 
regulatory feedback mechanism.  If there is a maximal level of MT1 expression in a cell, the 
transgenic expression may cause a reduction in endogenous MT1 in order to maintain this level, 
ultimately resulting in the same final amount of MT1 expressed. 
Additionally, it is important to note the dimerization of MT1 with itself, and as a 
heterodimer with MT2 or GPR50.   These are of particular interest due to their ability to reduce 
MT1 function when dimerized, with GPR50 providing the most striking reduction in function.  
While research is still determining the function of GPR50, some hypotheses point to it having a 
regulatory role in melatonin signaling.  In this case, GPR50 may modify the functionality of the 
transgenic MT1 without resulting in a reduction of MT1 expression; this would account for a mild 
but not strong effect of MT1 overexpression.  Future studies may benefit from knocking down 
GPR50 expression to determine whether a reduction in its ability to dimerize with MT1 results in 
stronger transgenic MT1 functionality and protective effects. 
In addition to receptor changes, another factor affecting these outcomes is melatonin’s role 
as an antioxidant.  The HD phenotype has many molecular effects including both apoptotic 
dysfunction and oxidative damage.  While these experiments focused on melatonin’s role in 
inhibiting apoptosis, it may also provide neuroprotection as an antioxidant.  Reactive oxygen 
species (ROS) are formed as a by-product of oxidative phosphorylation, the process by which ATP 
is produced in the mitochondria.  Build-up of ROS in cells causes mitochondria damage, which is 
detected by BCL-2 family proteins on the mitochondria, triggering apoptotic cell death.  In HD, 
there is an overproduction of ROS, increasing mitochondria and cell damage116.  Melatonin 
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functions as an antioxidant, and it may protect against neuronal death by reducing oxidative 
damage in mitochondria and preventing apoptotic cell death in that manner.  
The caspase activation changes paired with the neuropathological and behavioral 
phenotypic outcomes in the NSE-MT1-R6/2 compared to R6/2 alone increase our understanding 
of the strengths and limitations of melatonin-mediated neuroprotection.  This provides key insight 
into MT1-mediated neuroprotection, an important mechanism for modifying the disease outcome.  
The data strengthens evidence for caspase reduction as a means of neuroprotection.  However, 
there are notable limitations with the aggressive nature of the disease as modeled in R6/2 mice as 
well as the variety of unknown co-regulators which may impact the outcomes beyond MT1’s 
effects alone.  Combined with research in the field of understanding the pathology of HD and 
development of melatonergic drugs, my work provides a foundation for better understanding how 
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